Chakshu Research, Inc.

Chakshu Research, Inc., founded in California in 2002, is an active specialty pharmaceutical company focused on developing topical treatments—most notably its lead candidate C-KAD Ophthalmic Solution—for degenerative ocular diseases such as age-related cataracts and potentially glaucoma. Its main asset has reached Phase II clinical testing with promising early safety data and trends toward efficacy improvement over placebo. The firm operates privately from Los Gatos with academic ties through board members like Dr. Randall Olson but does not appear to have major industry partnerships or licensing deals disclosed publicly as of early/mid–2025.